<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990780</url>
  </required_header>
  <id_info>
    <org_study_id>SCHLC010</org_study_id>
    <nct_id>NCT02990780</nct_id>
  </id_info>
  <brief_title>Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC</brief_title>
  <official_title>Phase III Randomized Study of Induction Chemotherapy Followed By Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Stage Small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a phase III randomized controlled trial (RCT) evaluating the efficacy of
      induction chemotherapy followed by accelerated hypofractionated vs. conventionally
      fractionated concurrent chemo-radiotherapy for limited-stage small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Small-cell lung cancer accounts for approximately 13% of all lung cancers, and one-third of
      these patients present with limited stage SCLC at diagnosis. Currently the standard of care
      for LS-SCLC is concurrent chemotherapy and thoracic radiation therapy, with prophylactic
      cranial irradiation for those who achieve a good response after combined chemoradiotherapy,
      which has yielded a median survival of 15 to 23 months and 5-year survival rate up to 26%.

      The optimal dose/fraction for LS-SCLC remains debatable. For SCLC with the characteristic of
      rapid doubling time and high growth fraction, there is also evidence suggesting that
      prolonged or interrupted overall radiation time contributes to treatment failure and poor
      outcome because of accelerated repopulation.In our previous study we also found that overall
      radiation time might play an important role in the treatment of LS-SCLC and that patients
      treated with a high biologically effective dose (BED, including time factor) of &gt;57 Gy have
      favorable local control and survival.

      This is a randomised prospective phase III study based on patients with limited stage SCLC,
      defined as disease confined to one hemithorax and hilar,mediastinal, or supraclavicular nodes
      without pleural effusion, which can be safely encompassed within a tolerable radiation field.
      The purpose of this study is to add more information to the current medical literature about
      the efficacy and safety of accelerated hypofractionated vs. conventionally fractionated
      concurrent chemo-radiotherapy for limited-stage SCLC.

      Patients will be randomized into two groups. The control group will undergo the induction
      chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy.The
      experimental group will receive induction chemotherapy followed by accelerated
      hypofractionated concurrent chemo-radiotherapy.The investigators compare overall survival
      (OS) of the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse event</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional recurrence-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>SCLC</condition>
  <arm_group>
    <arm_group_label>Conventionally fractionated CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated hypofractionated CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventionally fractionated concurrent chemo-radiotherapy</intervention_name>
    <description>5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.</description>
    <arm_group_label>Conventionally fractionated CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated hypofractionated concurrent chemo-radiotherapy</intervention_name>
    <description>5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.</description>
    <arm_group_label>Accelerated hypofractionated CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed SCLC.

          -  Male or female, aged 18-70 years.

          -  ECOG performance status 0 to 2.

          -  Limited-stage SCLC was defined as disease confined to one hemithorax and
             hilar,mediastinal, or supraclavicular nodes without pleural effusion, which can be
             safely encompassed within a tolerable radiation field.

          -  No prior thoracic RT.

          -  Weight loss in six months less than or equal to five percent.

          -  FEV1 greater than 0.75L.

          -  No severe internal diseases and no organ dysfunction.

          -  No prior history of any tumor.

          -  Skin test of CT contrast agents was negative.

          -  Had received 1-6 cycles of VP16 plus DDP/carboplatin.

          -  Voluntarily participated in this study and signed the informed consent form by himself
             or his agent. Had good compliance with the study procedures, and can cooperate with
             the relevant examination, treatment and follow-up.

        Exclusion Criteria:

          -  Other tumor history(Except skin cancer/breast cancer/oral cancer/cervical cancer with
             expected lifespan more than or equal to 3 months).

          -  Multiple primary lung cancer.

          -  Any unstable systemic disease, including active infection, uncontrolled high blood
             pressure, unstable angina, newly observed angina pectoris within the past 3 months,
             congestive heart failure (New York heart association (NYHA) class II or higher),
             myocardial infarction onset six months before included into the group, and severe
             arrhythmia, liver, kidney, or metabolic disease in need of drug therapy. Human
             immunodeficiency virus (HIV) infection.

          -  Women in pregnancy or lactation .

          -  Patients with mental illness, considered as &quot;can't fully understand the issues of this
             research&quot;.

          -  Had received other chemotherapy regimens,any radiotherapy or TKI.

          -  Refuse to write informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaolong Fu, PhD</last_name>
    <phone>862122200000</phone>
    <phone_ext>3609</phone_ext>
    <email>xlfu1964@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiting Wang</last_name>
    <phone>862122200000</phone>
    <phone_ext>3609</phone_ext>
    <email>yitingwang_1111@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolong Fu, PhD</last_name>
      <phone>+862122200000</phone>
      <phone_ext>3602</phone_ext>
      <email>xlfu1964@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006 Oct 1;24(28):4539-44.</citation>
    <PMID>17008692</PMID>
  </reference>
  <reference>
    <citation>Bayman NA, Sheikh H, Kularatne B, Lorigan P, Blackhall F, Thatcher N, Faivre-Finn C. Radiotherapy for small-cell lung cancer-Where are we heading? Lung Cancer. 2009 Mar;63(3):307-14. doi: 10.1016/j.lungcan.2008.06.013. Epub 2008 Aug 3. Review.</citation>
    <PMID>18676057</PMID>
  </reference>
  <reference>
    <citation>Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187-95. doi: 10.1634/theoncologist.2009-0298. Epub 2010 Feb 9. Review.</citation>
    <PMID>20145192</PMID>
  </reference>
  <reference>
    <citation>Mamdani H, Induru R, Jalal SI. Novel therapies in small cell lung cancer. Transl Lung Cancer Res. 2015 Oct;4(5):533-44. doi: 10.3978/j.issn.2218-6751.2015.07.20. Review.</citation>
    <PMID>26629422</PMID>
  </reference>
  <reference>
    <citation>Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 2015 Jul 15;29(14):1447-62. doi: 10.1101/gad.263145.115. Review.</citation>
    <PMID>26220992</PMID>
  </reference>
  <reference>
    <citation>Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015 May 15;21(10):2244-55. doi: 10.1158/1078-0432.CCR-14-2958. Review.</citation>
    <PMID>25979931</PMID>
  </reference>
  <reference>
    <citation>Kalemkerian GP. Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother. 2014 Nov;15(16):2385-96. doi: 10.1517/14656566.2014.957180. Epub 2014 Sep 26. Review.</citation>
    <PMID>25255939</PMID>
  </reference>
  <reference>
    <citation>Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992 Dec 3;327(23):1618-24.</citation>
    <PMID>1331787</PMID>
  </reference>
  <reference>
    <citation>Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992 Jun;10(6):890-5.</citation>
    <PMID>1316951</PMID>
  </reference>
  <reference>
    <citation>Xia B, Chen GY, Cai XW, Zhao JD, Yang HJ, Fan M, Zhao KL, Fu XL. The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer. Radiat Oncol. 2011 May 19;6:50. doi: 10.1186/1748-717X-6-50.</citation>
    <PMID>21592406</PMID>
  </reference>
  <reference>
    <citation>De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006 Apr;17(4):543-52. Epub 2005 Dec 12. Review.</citation>
    <PMID>16344277</PMID>
  </reference>
  <reference>
    <citation>De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J, Lambin P. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006 Mar 1;24(7):1057-63.</citation>
    <PMID>16505424</PMID>
  </reference>
  <reference>
    <citation>Xia B, Chen GY, Cai XW, Zhao JD, Yang HJ, Fan M, Zhao KL, Fu XL. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer? Radiother Oncol. 2012 Feb;102(2):258-62. doi: 10.1016/j.radonc.2011.10.003. Epub 2011 Nov 5.</citation>
    <PMID>22056536</PMID>
  </reference>
  <reference>
    <citation>van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, Dingemans AM, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Teule J, Rhami A, Thimister W, Snoep G, Dehing-Oberije C, Lambin P. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):329-36. doi: 10.1016/j.ijrobp.2009.04.075. Epub 2009 Sep 24.</citation>
    <PMID>19782478</PMID>
  </reference>
  <reference>
    <citation>Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, Rivkin SE, Coltman CA Jr, Ward JH, Livingston RB. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol. 1987 Apr;5(4):592-600.</citation>
    <PMID>3031226</PMID>
  </reference>
  <reference>
    <citation>Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Eagan RT, Jett JR, Richardson RL, Creagan ET, Su JQ. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol. 1994 Mar;12(3):496-502.</citation>
    <PMID>8120547</PMID>
  </reference>
  <reference>
    <citation>Miller KL, Marks LB, Sibley GS, Clough RW, Garst JL, Crawford J, Shafman TD. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):355-9.</citation>
    <PMID>12738309</PMID>
  </reference>
  <reference>
    <citation>Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71.</citation>
    <PMID>9920950</PMID>
  </reference>
  <reference>
    <citation>Choi NC, Herndon JE 2nd, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998 Nov;16(11):3528-36.</citation>
    <PMID>9817271</PMID>
  </reference>
  <reference>
    <citation>Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003 Sep 20;362(9388):933-40. Erratum in: Lancet. 2003 Nov 8;362(9395):1588.</citation>
    <PMID>14511925</PMID>
  </reference>
  <reference>
    <citation>Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61. Epub 2007 Apr 30. Review.</citation>
    <PMID>17467926</PMID>
  </reference>
  <reference>
    <citation>Videtic GM, Fung K, Tomiak AT, Stitt LW, Dar AR, Truong PT, Yu EW, Vincent MD, Kocha WI. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer. 2001 Aug-Sep;33(2-3):249-58.</citation>
    <PMID>11551420</PMID>
  </reference>
  <reference>
    <citation>Xia B, Hong LZ, Cai XW, Zhu ZF, Liu Q, Zhao KL, Fan M, Mao JF, Yang HJ, Wu KL, Fu XL. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):517-23. doi: 10.1016/j.ijrobp.2014.09.042. Epub 2014 Dec 3.</citation>
    <PMID>25481679</PMID>
  </reference>
  <reference>
    <citation>Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012 Feb 10;30(5):525-32. doi: 10.1200/JCO.2010.33.3716. Epub 2012 Jan 17.</citation>
    <PMID>22253462</PMID>
  </reference>
  <reference>
    <citation>Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009 Aug;175(2):808-16. doi: 10.2353/ajpath.2009.090078. Epub 2009 Jul 23.</citation>
    <PMID>19628770</PMID>
  </reference>
  <reference>
    <citation>Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, Schouwink JH, Wijnands WJ, Kerner GS, Kruyt FA, Tissing H, Tibbe AG, Terstappen LW, Groen HJ. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 2012 Nov;23(11):2937-42. doi: 10.1093/annonc/mds138. Epub 2012 Jun 11.</citation>
    <PMID>22689177</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xiaolong Fu</investigator_full_name>
    <investigator_title>Director, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

